2477 results about "Pathogenicity" patented technology

A probe, a set of probes, and a probe carrier on which the probe or the set of probes is immobilized, are provided for classification of fungus species. The probe or the set of probes is capable of collectively detecting fungus of the same species and distinguishingly detecting those fungus from fungus of other species. The probe is an oligonucleotide probe for detecting a pathogenic fungus DNA and includes at least one of base sequences of SEQ ID NOS. 1 to 4 and mutated sequences thereof.

The present invention relates to a method for diagnosing and / or monitoring a bacterial or parasitic infection by detection and quantification of the transrenal nucleic acids, derived from bacterial pathogenic agents or from parasites, in urine. The detection method optionally includes the isolation and the purification of the nucleic acids from urine by methods known in the art including pairing with molecular probes that are specific for the pathogenic agents, PCR hybridization, PCR, nested PCR, SSCP, LCR, and SDA. Diagnostic kits based on these detection methods are also claimed.

Bacteria which co-express protease inhibitors and protease sensitive therapeutic agents, which are surface displayed, secreted and / or released and result in their localized production and maintenance within a target tissue and inactivation outside of the target tissue, thereby increasing therapeutic activity and reducing the systemic toxicity. The bacteria may be attenuated, non-pathogenic, low pathogenic or a probiotic. Protease sensitivity may be further accomplished by engineering protease degradation sites within the therapeutic agents, further enhancing the inactivation outside of the target tissue while retaining activity within the target tissue through co-expression of a protease inhibitor. Novel chimeric proteins secreted by bacteria, including chimeric toxins targeted to neoplastic cells, tumor matrix cells and cells of the immune system, and combination therapies of these protease inhibitor:chimeric toxin-expressing bacteria together with small-molecule and biologic agents are also described. Non-conjugative bacteria limiting exchange of genetic material, and antibody resistant bacteria are also provided.

The invention relates to a seedling stage identification method for the resistance of tobacco to the bacterial wilt. The seedling stage identification method comprises the steps of heat preservation pool construction, pool water heating and circulation, wilt bacterium inoculation, tobacco seedling, disease state investigation and grading. The method replaces a conventional field identification result with a seedling stage identification result, identifies a great amount of material in a smaller area, carries out the identification a plurality of times annually, improves the reliability of the result, shortens the identification cycle, saves the site and test cost, and covers little floor space. The seedling stage identification method for the resistance of tobacco to the bacterial wilt is characterized by rapid disease development, good result repeatability, and the like. The seedling stage identification method for the resistance of tobacco to the bacterial wilt can effectively remove the interference on the resistance result caused by soil temperature difference, strain pathogenicity difference, strain quantity difference and other diseases, thereby benefiting the recurrence and comparison of results from different years and different labs. The difference between the attack rates of infection resistant varieties and the disease indexes is obvious; and the appraisal result of the resistance of the variety is basically consistent with the perennial resistance appraisal result obtained by others. The method has greater application potential in the resistance identification and resistance heredity rule study of disease resistant resources and breeding medium materials.